Actively Recruiting

Phase Not Applicable
Age: 3Years +
All Genders
NCT07294547

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Led by National Taiwan University Hospital · Updated on 2025-12-19

80

Participants Needed

1

Research Sites

261 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients. Most hospitals prescribe valganciclovir for this purpose but valacyclovir has also been used. The most unfavorable side effect of valganciclovir is bone marrow suppression which can be troublesome for kidney transplant patients who are already immunosuppressed. We aim to assess the non-inferiority of valacyclovir compared with valganciclovir in this study.

CONDITIONS

Official Title

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

Who Can Participate

Age: 3Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age at least 3 years
  • Received or about to receive kidney transplant within 2 weeks before screening
  • Planned to receive antiviral prophylaxis against CMV and/or EBV as decided by transplant surgeon
  • No active CMV or EBV infection detected by viral load test at screening
  • Able and willing to provide informed consent and follow study procedures
Not Eligible

You will not qualify if you...

  • Severe health conditions that make participation unsafe as judged by transplant surgeon
  • Pregnancy (valganciclovir may cause harm to unborn babies)
  • Known allergy to both valacyclovir and valganciclovir

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National Taiwan University Hospital

Taipei, Taiwan

Actively Recruiting

Loading map...

Research Team

H

Hou-Xuan Huang, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here